Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
29 Sep 2014 European Medicines Agency Recommends Granting a Marketing Authorisation for Ramucirumab Gastrointestinal cancers - Anticancer agents & Biologic therapy
29 Sep 2014 ESMO 2014 Press Release: New Data on Combination Treatments for Melanoma Melanoma
29 Sep 2014 ESMO 2014 Press Release: Nivolumab Shows Signs of Superior Response Rate Compared to Standard Chemotherapy in Advanced Melanoma Melanoma - Immuno-oncology
29 Sep 2014 ESMO 2014 Press Release: Studies Report New Findings on Treatment Options for Mesothelioma Lung and other thoracic tumours - Immuno-oncology - Anticancer agents & Biologic therapy
28 Sep 2014 ESMO 2014: Adjuvant Treatment with MAGE-A3 Cancer Immunotherapeutic in Patients with Resected NSCLC Does Not Increase Disease-Free Survival Lung and other thoracic tumours - Immuno-oncology
28 Sep 2014 ESMO 2014: Final Overall Survival Analysis from the CLEOPATRA Study in Patients with HER2-Positive Metastatic Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
28 Sep 2014 ESMO 2014: Final Overall Survival Analysis of the Phase III Randomised Trial of Chemotherapy With and Without Bevacizumab for Advanced Cervical Cancer Gynaecologic malignancies - Anticancer agents & Biologic therapy
28 Sep 2014 ESMO 2014: Activity of Second-Line Dovitinib in Advanced and/or Metastatic Endometrial Cancer Gynaecologic malignancies - Anticancer agents & Biologic therapy
28 Sep 2014 ESMO 2014: Continuation of Gefitinib Plus Pemetrexed/Cisplatin of No Clinical Benefit in NSCLC Patients with Acquired Resistance to Gefitinib Lung and other thoracic tumours - Anticancer agents & Biologic therapy
28 Sep 2014 ESMO 2014 Press Release: Treatments for Advanced Cancer Less Available in Eastern Europe, Reveals ESMO Survey Bioethics, legal and economic issues
28 Sep 2014 ESMO 2014 Press Commentary: CLEOPATRA Trial Changes Standard Therapy for Metastatic HER2 Positive Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
28 Sep 2014 ESMO 2014 Press Release: MAGRIT Phase III Trial Results Raise Questions About the Future of Lung Cancer Vaccination Lung and other thoracic tumours - Immuno-oncology
28 Sep 2014 ESMO 2014: Bevacizumab Maintenance in HER2-Negative Metastatic Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
28 Sep 2014 The Promise of Tumour-Infiltrating Lymphocytes for Cancer Treatment and as Prognostic/Predictive Indicators Breast cancer - Immuno-oncology
28 Sep 2014 How an Understanding of Melanoma Development is Changing the Clinical Landscape of its Treatment Melanoma